Allogene Therapeutics, Inc. Increase (Decrease) in Prepaid Expense and Other Assets
Allogene Therapeutics, Inc. (ALLO) reported Increase (Decrease) in Prepaid Expense and Other Assets of -$143.00 thousand for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-12.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets · last filed 2026-08-12
- Allogene Therapeutics, Inc. increase (decrease) in prepaid expense and other assets for the quarter ending 2026-06-30 was $989.00K.
- Allogene Therapeutics, Inc. increase (decrease) in prepaid expense and other assets for the quarter ending 2026-03-31 was -$1.13M, a 281.70% decline year-over-year.
- Allogene Therapeutics, Inc. increase (decrease) in prepaid expense and other assets for the quarter ending 2025-12-31 was -$986.00K.
- Allogene Therapeutics, Inc. increase (decrease) in prepaid expense and other assets for the quarter ending 2025-09-30 was -$1.01M, a 396.19% decline year-over-year.
- Allogene Therapeutics, Inc. increase (decrease) in prepaid expense and other assets for fiscal 2025 was -$3.24M, a 758.13% decline from fiscal 2024.
- Allogene Therapeutics, Inc. increase (decrease) in prepaid expense and other assets for fiscal 2024 was $492.00K.
- Allogene Therapeutics, Inc. increase (decrease) in prepaid expense and other assets for fiscal 2023 was -$1.09M.
- Allogene Therapeutics, Inc. increase (decrease) in prepaid expense and other assets for fiscal 2022 was -$2.52M.
| Period end | Increase (Decrease) in Prepaid Expense and Other Assets 1 month | Increase (Decrease) in Prepaid Expense and Other Assets 3 month | Increase (Decrease) in Prepaid Expense and Other Assets 6 month | Increase (Decrease) in Prepaid Expense and Other Assets 9 month | Increase (Decrease) in Prepaid Expense and Other Assets 12 month |
|---|---|---|---|---|---|
| 2026-06-30 | $989.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-12 | -$143.00K 10-Q · filed 2026-08-12 | -$1.13M derived: sum of 3 quarters · filed 2026-08-12 | -$2.14M derived: sum of 4 quarters · filed 2026-08-12 | |
| 2026-03-31 | -$1.13M 10-Q · filed 2026-05-13 | -$2.12M derived: sum of 2 quarters · filed 2026-05-13 | -$3.13M derived: sum of 3 quarters · filed 2026-05-13 | -$4.99M derived: sum of 4 quarters · filed 2026-08-12 | |
| 2025-12-31 | -$986.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-12 | -$2.00M derived: sum of 2 quarters · filed 2026-03-12 | -$3.86M derived: sum of 3 quarters · filed 2026-08-12 | -$3.24M 10-K · filed 2026-03-12 | |
| 2025-09-30 | -$1.01M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | -$2.88M derived: sum of 2 quarters · filed 2026-08-12 | -$2.25M 10-Q · filed 2025-11-06 | -$4.05M derived: sum of 4 quarters · filed 2026-08-12 | |
| 2025-06-30 | -$1.86M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-12 | -$1.24M 10-Q · filed 2026-08-12 | -$3.04M derived: sum of 3 quarters · filed 2026-08-12 | -$2.70M derived: sum of 4 quarters · filed 2026-08-12 | |
| 2025-03-31 | $623.00K 10-Q · filed 2026-05-13 | -$1.18M derived: sum of 2 quarters · filed 2026-05-13 | -$838.00K derived: sum of 3 quarters · filed 2026-05-13 | $1.03M derived: sum of 4 quarters · filed 2026-05-13 | |
| 2024-12-31 | -$1.80M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-12 | -$1.46M derived: sum of 2 quarters · filed 2026-03-12 | $406.00K derived: sum of 3 quarters · filed 2026-03-12 | $492.00K 10-K · filed 2026-03-12 | |
| 2024-09-30 | $341.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | $2.21M derived: sum of 2 quarters · filed 2025-11-06 | $2.29M 10-Q · filed 2025-11-06 | $4.76M derived: sum of 4 quarters · filed 2025-11-06 | |
| 2024-06-30 | $1.87M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-13 | $1.95M 10-Q · filed 2025-08-13 | $4.42M derived: sum of 3 quarters · filed 2025-08-13 | $2.23M derived: sum of 4 quarters · filed 2025-08-13 | |
| 2024-03-31 | $86.00K 10-Q · filed 2025-05-13 | $2.56M derived: sum of 2 quarters · filed 2025-05-13 | $365.00K derived: sum of 3 quarters · filed 2025-05-13 | $263.00K derived: sum of 4 quarters · filed 2025-05-13 | |
| 2023-12-31 | $2.47M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-13 | $279.00K derived: sum of 2 quarters · filed 2025-03-13 | $177.00K derived: sum of 3 quarters · filed 2025-03-13 | -$1.09M 10-K · filed 2025-03-13 | |
| 2023-09-30 | -$2.19M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-07 | -$2.29M derived: sum of 2 quarters · filed 2024-11-07 | -$3.56M 10-Q · filed 2024-11-07 | -$8.88M derived: sum of 4 quarters · filed 2024-11-07 | |
| 2023-06-30 | -$102.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-07 | -$1.36M 10-Q · filed 2024-08-07 | -$6.69M derived: sum of 3 quarters · filed 2024-08-07 | -$12.40M derived: sum of 4 quarters · filed 2024-08-07 | |
| 2023-03-31 | -$1.26M 10-Q · filed 2024-05-13 | -$6.59M derived: sum of 2 quarters · filed 2024-05-13 | -$12.29M derived: sum of 3 quarters · filed 2024-05-13 | -$10.45M derived: sum of 4 quarters · filed 2024-05-13 | |
| 2022-12-31 | -$5.33M derived: 10-K/A 12 month − 10-Q 9 month · filed 2024-03-14 | -$11.03M derived: sum of 2 quarters · filed 2024-03-14 | -$9.19M derived: sum of 3 quarters · filed 2024-03-14 | -$2.52M 10-K/A · filed 2024-03-14 | |
| 2022-09-30 | -$5.70M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-02 | -$3.86M derived: sum of 2 quarters · filed 2023-11-02 | $2.81M 10-Q · filed 2023-11-02 | -$2.54M derived: sum of 4 quarters · filed 2024-03-14 | |
| 2022-06-30 | $1.84M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-02 | $8.52M 10-Q · filed 2023-08-02 | $3.16M derived: sum of 3 quarters · filed 2024-03-14 | $8.07M derived: sum of 4 quarters · filed 2024-03-14 | |
| 2022-03-31 | $6.67M 10-Q · filed 2023-05-03 | $1.32M derived: sum of 2 quarters · filed 2024-03-14 | $6.23M derived: sum of 3 quarters · filed 2024-03-14 | $4.21M derived: sum of 4 quarters · filed 2024-03-14 | |
| 2021-12-31 | -$5.35M derived: 10-K/A 12 month − 10-Q 9 month · filed 2024-03-14 | -$444.00K derived: sum of 2 quarters · filed 2024-03-14 | -$2.46M derived: sum of 3 quarters · filed 2024-03-14 | -$3.20M 10-K/A · filed 2024-03-14 | |
| 2021-09-30 | $4.91M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-02 | $2.89M derived: sum of 2 quarters · filed 2022-11-02 | $2.15M 10-Q · filed 2022-11-02 | $5.99M derived: sum of 4 quarters · filed 2024-03-14 | |
| 2021-06-30 | -$2.02M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-09 | -$2.75M 10-Q · filed 2022-08-09 | $1.08M derived: sum of 3 quarters · filed 2024-03-14 | $4.54M derived: sum of 4 quarters · filed 2024-03-14 | |
| 2021-03-31 | -$740.00K 10-Q · filed 2022-05-04 | $3.09M derived: sum of 2 quarters · filed 2024-03-14 | $6.55M derived: sum of 3 quarters · filed 2024-03-14 | $4.99M derived: sum of 4 quarters · filed 2024-03-14 | |
| 2020-12-31 | $3.83M derived: 10-K/A 12 month − 10-Q 9 month · filed 2024-03-14 | $7.29M derived: sum of 2 quarters · filed 2024-03-14 | $5.73M derived: sum of 3 quarters · filed 2024-03-14 | $3.18M 10-K/A · filed 2024-03-14 | |
| 2020-09-30 | $3.46M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-04 | $1.90M derived: sum of 2 quarters · filed 2021-11-04 | -$657.00K 10-Q · filed 2021-11-04 | $4.87M derived: sum of 4 quarters · filed 2022-02-23 | |
| 2020-06-30 | -$1.56M derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-04 | -$4.12M 10-Q · filed 2021-08-04 | $1.42M derived: sum of 3 quarters · filed 2022-02-23 | $808.00K derived: sum of 4 quarters · filed 2022-02-23 | |
| 2020-03-31 | -$2.55M 10-Q · filed 2021-05-05 | $2.98M derived: sum of 2 quarters · filed 2022-02-23 | $2.37M derived: sum of 3 quarters · filed 2022-02-23 | $1.00M derived: sum of 4 quarters · filed 2022-02-23 | |
| 2019-12-31 | $5.53M derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-23 | $4.92M derived: sum of 2 quarters · filed 2022-02-23 | $3.55M derived: sum of 3 quarters · filed 2022-02-23 | $5.45M 10-K · filed 2022-02-23 | |
| 2019-09-30 | -$607.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-04 | -$1.98M derived: sum of 2 quarters · filed 2020-11-04 | -$86.00K 10-Q · filed 2020-11-04 | $5.38M derived: sum of 4 quarters · filed 2021-02-25 | |
| 2019-06-30 | -$1.37M derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-05 | $521.00K 10-Q · filed 2020-08-05 | $5.99M derived: sum of 3 quarters · filed 2021-02-25 | $8.78M derived: sum of 4 quarters · filed 2021-02-25 | |
| 2019-03-31 | $1.89M 10-Q · filed 2020-05-06 | $7.36M derived: sum of 2 quarters · filed 2021-02-25 | $10.15M derived: sum of 3 quarters · filed 2021-02-25 | $10.49M derived: sum of 4 quarters · filed 2021-02-25 | |
| 2018-12-31 | $5.47M derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-25 | $8.26M derived: sum of 2 quarters · filed 2021-02-25 | $8.60M derived: sum of 3 quarters · filed 2021-02-25 | $8.60M 10-K · filed 2021-02-25 | |
| 2018-09-30 | $2.79M derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-05 | $3.14M derived: sum of 2 quarters · filed 2019-11-05 | $3.13M 10-Q · filed 2019-11-05 | ||
| 2018-06-30 | $342.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-07 | $337.00K 10-Q · filed 2019-08-07 | |||
| 2018-03-31 | -$5.00K 10-Q · filed 2019-05-07 | ||||
| 2017-12-31 | $0.00 10-K · filed 2020-02-27 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Prime Medicine, Inc. (PRME) | United States | $0.557B | -3.54 |
| Aura Biosciences, Inc. (AURA) | United States | $0.639B | -5.61 |
| Autolus Therapeutics plc (AUTL) | $0.506B | -1.52 | |
| Entera Bio Ltd. (ENTX) | $0.485B | ||
| REGENXBIO Inc. (RGNX) | United States | $0.477B | -3.30 |
| Tectonic Therapeutic, Inc. (TECX) | United States | $0.469B | -7.68 |
| Eikon Therapeutics, Inc. (EIKN) | United States | $0.446B | |
| Kyverna Therapeutics, Inc. (KYTX) | United States | $0.434B | -3.60 |
| Editas Medicine, Inc. (EDIT) | United States | $0.424B | -4.29 |
| 4D Molecular Therapeutics, Inc. (FDMT) | United States | $0.733B | -4.10 |